NTI Neurotech International Limited
—Mkt Cap: —P/E: —1d ago
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Au…
Industry Peers
Health Information Services$50.68BUSDP/E 52.1
$12.83BUSD
$12.34BUSDP/E 55.2
$8.47BUSDP/E 34.6
$7.65BUSDP/E 33.5
$5.61BUSDP/E 37.1
$5.41BUSDP/E 39.2
$4.43BUSD
$2.89BUSDP/E 107.7
$1.91BUSD
$1.64BUSDP/E 43.8
$1.47BUSD
$1.20BUSDP/E 70.1
$1.14BUSDP/E 77.8
$1.08BUSD
$1.03BUSDP/E 46.9
$685.26MUSDP/E 64.9
$620.58MUSD
$594.53MUSD
$580.72MUSDP/E 31.4
Key Statistics
Company
Market Cap—
Enterprise Value13.89M USD
Revenue (TTM)3.27M USD
Gross Profit164 USD
Net Income (TTM)-7.32M USD
Revenue/Share0.0040 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryHealth Information Services
ISINAU000000NTI9
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.04
EV/Revenue4.25
P/S4.75
P/B—
EPS (TTM)-0.01
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin83308.73%
EBITDA Margin-139.64%
Profit Margin-4453302.10%
ROE-358.73%
ROA-327.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.92M USD
CapEx (TTM)—
FCF Margin-38.47%
FCF Yield—
Net Debt-1.65M USD
Net Debt/EBITDA0.36
Balance Sheet
Debt/Equity—
Current Ratio1.29
Quick Ratio1.28
Book Value/Sh0.00 AUD
Cash/Share0.0020 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.32B
Float1.01B
Insiders27.20%
Institutions4.42%
Technical
SMA 500.0138 AUD
SMA 2000.0137 AUD
Beta0.01
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)10.28M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—